SU11271

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406406

CAS#: 669764-16-3

Description: SU11271 is a potent c-MET inhibitor with potential anticancer activity.


Price and Availability

Size
Price

Size
Price

Size
Price

SU11271 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406406
Name: SU11271
CAS#: 669764-16-3
Chemical Formula: C29H31N5O4S
Exact Mass: 545.20968
Molecular Weight: 545.65
Elemental Analysis: C, 63.83; H, 5.73; N, 12.83; O, 11.73; S, 5.88


Synonym: SU11271; SU11271; SU 11271.

IUPAC/Chemical Name: (Z)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-5-(indolin-1-ylsulfonyl)indolin-2-one

InChi Key: MHTSQKQLTZCFPE-QJOMJCCJSA-N

InChi Code: InChI=1S/C29H31N5O4S/c1-18-25(30-19(2)27(18)29(36)33-14-12-32(3)13-15-33)17-23-22-16-21(8-9-24(22)31-28(23)35)39(37,38)34-11-10-20-6-4-5-7-26(20)34/h4-9,16-17,30H,10-15H2,1-3H3,(H,31,35)/b23-17-

SMILES Code: O=C1NC2=C(C=C(S(=O)(N3CCC4=C3C=CC=C4)=O)C=C2)/C1=C/C5=C(C)C(C(N6CCN(C)CC6)=O)=C(C)N5


Technical Data

Appearance:
yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1. La Monica, Silvia; Caffarra, Cristina; Saccani, Francesca; Galvani, Elena; Galetti, Maricla; Fumarola, Claudia; Bonelli, Mara; Cavazzoni, Andrea; Cretella, Daniele; Sirangelo, Rita; et al. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One (2013), 8(10), e78656.

2. Golub, Todd; Straussman, Ravid. Methods of treating cancer using a chemotherapeutic agent with an agent that blocks the activity of hepatocyte growth factor or its cognate receptor c-MET. PCT Int. Appl. (2012), WO 2012178038 A1 20121227

3. Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Molecular Cancer Therapeutics (2003), 2(11), 1085-1092.